Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway
Atherosclerosis remains a great threat to human health worldwide. Previous studies found that tetramethylpyrazine (TMP) and paeonif lorin (PF) combination (TMP-PF) exerts anti-atherosclerotic effects in vitro. However, whether TMP-PF improves atherosclerosis in vivo needs further exploration. The pr...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tsinghua University Press
2024-09-01
|
| Series: | Food Science and Human Wellness |
| Subjects: | |
| Online Access: | https://www.sciopen.com/article/10.26599/FSHW.2022.9250212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841550099354746880 |
|---|---|
| author | Rong Yuan Qiqi Xin Weili Shi Yu Miao Zhengchuan Zhu Yahui Yuan Ying Chen Xiaoning Chen Sean Xiao Leng Keji Chen Weihong Cong |
| author_facet | Rong Yuan Qiqi Xin Weili Shi Yu Miao Zhengchuan Zhu Yahui Yuan Ying Chen Xiaoning Chen Sean Xiao Leng Keji Chen Weihong Cong |
| author_sort | Rong Yuan |
| collection | DOAJ |
| description | Atherosclerosis remains a great threat to human health worldwide. Previous studies found that tetramethylpyrazine (TMP) and paeonif lorin (PF) combination (TMP-PF) exerts anti-atherosclerotic effects in vitro. However, whether TMP-PF improves atherosclerosis in vivo needs further exploration. The present study aims to assess the anti-atherosclerotic properties of TMP-PF in ApoE-/- mice and explore the related molecule mechanisms. Results showed that TMP and high-dose TMP-PF decreased serum triglyceride and low-density lipoprotein cholesterol levels, suppressed vascular endothelial growth factor receptor 2 (VEGFR2) and nuclear receptor subfamily 4 group A member 1 (NR4A1) expression in aortic tissues, inhibited plaque angiogenesis, reduced plaque areas, and alleviated atherosclerosis in ApoE-/- mice. Also, TMP-PF exhibited a better modulation effect than TMP or PF alone. However, NR4A1 agonist abolished the anti-atherosclerotic effects of TMP-PF. In conclusion, TMP-PF was first found to alleviate atherosclerosis progression by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway, indicating that TMP-PF had a positive effect on reducing hyperlipemia and attenuating atherosclerosis development. |
| format | Article |
| id | doaj-art-4e45114eb37f467b977ff97733e9de48 |
| institution | Kabale University |
| issn | 2097-0765 2213-4530 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Tsinghua University Press |
| record_format | Article |
| series | Food Science and Human Wellness |
| spelling | doaj-art-4e45114eb37f467b977ff97733e9de482025-01-10T06:56:56ZengTsinghua University PressFood Science and Human Wellness2097-07652213-45302024-09-011352642265210.26599/FSHW.2022.9250212Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathwayRong Yuan0Qiqi Xin1Weili Shi2Yu Miao3Zhengchuan Zhu4Yahui Yuan5Ying Chen6Xiaoning Chen7Sean Xiao Leng8Keji Chen9Weihong Cong10Cardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaSchool of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing 210023, ChinaDepartment of Otolaryngology, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, ChinaDivision of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore 21224, United StatesCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaCardiovascular Diseases Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaAtherosclerosis remains a great threat to human health worldwide. Previous studies found that tetramethylpyrazine (TMP) and paeonif lorin (PF) combination (TMP-PF) exerts anti-atherosclerotic effects in vitro. However, whether TMP-PF improves atherosclerosis in vivo needs further exploration. The present study aims to assess the anti-atherosclerotic properties of TMP-PF in ApoE-/- mice and explore the related molecule mechanisms. Results showed that TMP and high-dose TMP-PF decreased serum triglyceride and low-density lipoprotein cholesterol levels, suppressed vascular endothelial growth factor receptor 2 (VEGFR2) and nuclear receptor subfamily 4 group A member 1 (NR4A1) expression in aortic tissues, inhibited plaque angiogenesis, reduced plaque areas, and alleviated atherosclerosis in ApoE-/- mice. Also, TMP-PF exhibited a better modulation effect than TMP or PF alone. However, NR4A1 agonist abolished the anti-atherosclerotic effects of TMP-PF. In conclusion, TMP-PF was first found to alleviate atherosclerosis progression by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway, indicating that TMP-PF had a positive effect on reducing hyperlipemia and attenuating atherosclerosis development.https://www.sciopen.com/article/10.26599/FSHW.2022.9250212atherosclerosishyperlipemiaangiogenesisplaque stabilitychinese medicinetetramethylpyrazinepaeoniflorin |
| spellingShingle | Rong Yuan Qiqi Xin Weili Shi Yu Miao Zhengchuan Zhu Yahui Yuan Ying Chen Xiaoning Chen Sean Xiao Leng Keji Chen Weihong Cong Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway Food Science and Human Wellness atherosclerosis hyperlipemia angiogenesis plaque stability chinese medicine tetramethylpyrazine paeoniflorin |
| title | Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway |
| title_full | Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway |
| title_fullStr | Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway |
| title_full_unstemmed | Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway |
| title_short | Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway |
| title_sort | tetramethylpyrazine and paeoniflorin combination tmp pf alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the nr4a1 vegfr2 pathway |
| topic | atherosclerosis hyperlipemia angiogenesis plaque stability chinese medicine tetramethylpyrazine paeoniflorin |
| url | https://www.sciopen.com/article/10.26599/FSHW.2022.9250212 |
| work_keys_str_mv | AT rongyuan tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT qiqixin tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT weilishi tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT yumiao tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT zhengchuanzhu tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT yahuiyuan tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT yingchen tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT xiaoningchen tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT seanxiaoleng tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT kejichen tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway AT weihongcong tetramethylpyrazineandpaeoniflorincombinationtmppfalleviatesatherosclerosisprogressbyreducinghyperlipemiaandinhibitingplaqueangiogenesisviathenr4a1vegfr2pathway |